Original ResearchFull Report: Clinical—Alimentary TractRisk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
Graphical abstract
Section snippets
Data Sources
This cohort study was based on the French National Health Insurance database (Système National d'Information Inter-Régimes de l'Assurance Maladie, SNIIRAM),15 which covers 95% of the French population with different insurance schemes based on employment situation. The general health insurance scheme covers employees in the industry, business, and service sectors; public service employees, and students, accounting for approximately 88% of the French population. Because of data availability and
Characteristics of the Cohort
Among the 246,704 individuals 18 years or older identified with IBD before 2014, 190,694 were included in the main analysis (Figure 1). During follow-up, 128,285 (67.3%) had never been exposed to thiopurines and anti-TNFs, and 572 (24.9%), 26,255 (13.8%), and 12,023 (6.3%) had ever been exposed to thiopurine monotherapy, anti-TNF monotherapy, and combination therapy, respectively, accounting for 109,177; 57,835; and 11,143 person-years (PY) of follow-up.
Overall, patients were predominantly
Discussion
Based on a large population-based, nationwide cohort study, our findings suggest that among patients with IBD, the risks of serious and opportunistic infections are higher with combination therapy than with thiopurine monotherapy or anti-TNF monotherapy. In addition, the risks of serious infections and of mycobacterial and opportunistic bacterial infections are increased with anti-TNF monotherapy compared with thiopurine monotherapy. However, the risk of opportunistic infections with anti-TNF
References (32)
- et al.
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis
Gastroenterology
(2014) - et al.
Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J Crohns Colitis
(2014) - et al.
Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis
Clin Gastroenterol Hepatol
(2016) - et al.
Effectiveness and safety of immunomodulators with anti–tumor necrosis factor therapy in Crohn’s disease
Clin Gastroenterol Hepatol
(2015) - et al.
French national health insurance information system and the permanent beneficiaries sample
Rev DÉpidémiologie Santé Publique
(2010) - et al.
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study
Lancet Haematol
(2015) - et al.
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Gastroenterology
(2008) - et al.
Increasing incidence and prevalence of the inflammatory bowel diseases. with time, based on systematic review
Gastroenterology
(2012) - et al.
Infliximab, azathioprine, or combination therapy for Crohn’s disease
N Engl J Med
(2010) - et al.
3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: surgical management and special situations
J Crohns Colitis
(2016)
Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management
J Crohns Colitis
Cancers complicating inflammatory bowel disease
N Engl J Med
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
BMJ
Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREATTM registry
Am J Gastroenterol
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases
JAMA
Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease
Eur J Gastroenterol Hepatol
Cited by (0)
Conflicts of interest Franck Carbonnel has received consulting fees from Genentech, Otsuka, and Vifor and lecture fees from Hospira. Fabrice Carrat has received consulting fees from Imaxio. The remaining authors disclose no conflicts.
Funding There was no funding source for this study.
Author names in bold designate shared co-first authorship.